ADC Therapeutics SA (ADCT)

The company’s lead marketed medicine is ZYNLONTA, also known as loncastuximab tesirine. It is a CD19-directed antibody-drug conjugate approved by the US Food and Drug Administration for certain adult patients with relapsed or refractory large B-cell lymphoma after two or more prior lines of systemic therapy. This places ADC Therapeutics in the market for difficult-to-treat hematologic cancers, where patients often have limited options after standard therapies fail.

Beyond its commercial product, ADC Therapeutics maintains a clinical and preclinical development pipeline aimed at expanding the use of its platform across blood cancers and solid tumors. Programs referenced by the company include studies such as LOTIS-2, LOTIS-5, LOTIS-7, and ADCT-241, which explore different treatment settings, combinations, or targets in oncology.

Revenue is primarily tied to the commercialization of ZYNLONTA, with the United States representing the company’s largest market, followed by regions including Europe, the Middle East, and Africa. As a biotechnology stock, ADCT is shaped by product sales, clinical trial results, regulatory decisions, competition from other lymphoma therapies, manufacturing execution, and the company’s ability to fund research while advancing its pipeline.